# Minerva Neuroscience (NERV) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/NERV
## Company Profile
- Ticker: NERV
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 3.92 USD
- Market cap: 221296367.75 USD
- Last updated: 2026-08-12
## Business Overview
### CNS Drug Development
Minerva Neurosciences develops therapies for central nervous system disorders. Its lead program focuses specifically on negative symptoms of schizophrenia, an area with limited approved treatment options.
### Roluperidone
Roluperidone is an investigational oral therapy intended to improve primary negative symptoms such as social withdrawal, reduced emotional expression and lack of motivation. Earlier studies demonstrated clinically meaningful effects without relying on dopamine D2 blockade.
### Confirmatory Registration Path
Minerva has general FDA alignment on a confirmatory Phase 3 study using a design similar to its prior trials. The approximately 380-patient first phase will compare 64 mg roluperidone with placebo over 12 weeks and is intended to support NDA resubmission.
## Why The Stock Is Moving

As of Aug 12, 2026, NERV closed down 9.26% at $3.92. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initiation of the confirmatory Phase 3 roluperidone trial planned for the second quarter of 2026.
- Topline Phase 3 data anticipated in the second half of 2027.
- Potential NDA resubmission following successful completion of the confirmatory study.

## Recent News
- 2026-08-07 11:00 EST — [Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/NERV/minerva-neurosciences-provides-second-quarter-2026-financial-results-and-busines-c01af06c) — Source: Minerva Neuroscience
- 2026-06-01 20:05 EST — [Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs](https://biopharmsignal.com/news/NERV/minerva-neurosciences-establishes-scientific-advisory-board-to-advance-development-of-roluperidone-and-future-pipeline-programs) — Source: Minerva Neuroscience
- 2026-05-18 20:05 EST — [Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/NERV/minerva-neurosciences-to-participate-in-the-2026-jefferies-global-healthcare-conference) — Source: Minerva Neuroscience
- 2026-05-05 12:00 EST — [Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/NERV/minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates) — Source: Minerva Neuroscience
- 2026-04-02 20:05 EST — [Minerva Announces Leadership Transition](https://biopharmsignal.com/news/NERV/minerva-announces-leadership-transition) — Source: Minerva Neuroscience